Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18368410rdf:typepubmed:Citationlld:pubmed
pubmed-article:18368410lifeskim:mentionsumls-concept:C0295352lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C1708300lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C0224522lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C0040284lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C1514559lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C1415809lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:18368410lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:18368410pubmed:issue10lld:pubmed
pubmed-article:18368410pubmed:dateCreated2008-7-11lld:pubmed
pubmed-article:18368410pubmed:abstractTextSerotonin antagonists show impressive analgesic efficacy in rheumatoid arthritis, osteoarthritis (OA) or fibromyalgia; however, this effect is not well understood. We examined the mechanism of serotonin-induced inflammation and its antagonists in OA. Serotonin receptor subtypes and COX-2 were analysed by RT-PCR from synovial tissue. Serum-free cultures were stimulated with 10 muM serotonin and/or the antagonists ketanserin (5-HT(2A)), tropisetron (5-HT(3)) and parecoxib (COX-2). Prostaglandin E(2) (PGE(2)), tumour necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and leukotriene B4 (LTB4) were measured by an immunoassay in the supernatants. RT-PCR results showed mRNA for 5-HT(2A) and 5-HT(3) receptors, and COX-2. PGE(2) in the supernatants increased by 261.2% +/- 56.7 (mean +/- SEM; P = 0.007) in response to serotonin. TNF-alpha, IL-1beta and LTB4 levels did not change. Ketanserin, tropisetron and parecoxib suppressed PGE(2). The serotonin-induced PGE(2) overexpression appeared thus to be mediated by 5-HT(2A) and 5-HT(3) receptors. This activation might involve COX-2. The findings may explain the potent benefit of 5-HT(3) antagonists.lld:pubmed
pubmed-article:18368410pubmed:languageenglld:pubmed
pubmed-article:18368410pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:citationSubsetIMlld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18368410pubmed:statusMEDLINElld:pubmed
pubmed-article:18368410pubmed:monthAuglld:pubmed
pubmed-article:18368410pubmed:issn0172-8172lld:pubmed
pubmed-article:18368410pubmed:authorpubmed-author:VetterHansHlld:pubmed
pubmed-article:18368410pubmed:authorpubmed-author:Candelario-Ja...lld:pubmed
pubmed-article:18368410pubmed:authorpubmed-author:FiebichBernd...lld:pubmed
pubmed-article:18368410pubmed:authorpubmed-author:Ulrich-Merzen...lld:pubmed
pubmed-article:18368410pubmed:authorpubmed-author:SeidelMatthia...lld:pubmed
pubmed-article:18368410pubmed:authorpubmed-author:KochFranz-Wal...lld:pubmed
pubmed-article:18368410pubmed:issnTypePrintlld:pubmed
pubmed-article:18368410pubmed:volume28lld:pubmed
pubmed-article:18368410pubmed:ownerNLMlld:pubmed
pubmed-article:18368410pubmed:authorsCompleteYlld:pubmed
pubmed-article:18368410pubmed:pagination1017-22lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:meshHeadingpubmed-meshheading:18368410...lld:pubmed
pubmed-article:18368410pubmed:year2008lld:pubmed
pubmed-article:18368410pubmed:articleTitleSerotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cells.lld:pubmed
pubmed-article:18368410pubmed:affiliationRheumatology, Medizinische Universitäts-Poliklink, Bonn, Germany. Matthias.Seidel@ukb.uni-bonn.delld:pubmed
pubmed-article:18368410pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18368410pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3356entrezgene:pubmedpubmed-article:18368410lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18368410lld:entrezgene